Actively Recruiting
KAN-004 for Immune-Related Diarrhea or Colitis
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2026-04-13
21
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the safety and tolerability of KAN-004 in patients with immune-related colitis.
CONDITIONS
Official Title
KAN-004 for Immune-Related Diarrhea or Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of solid tumor treated with immune checkpoint inhibitor (at least 1 cycle, within 180 days since last cycle)
- Clinical diagnosis of immune-related colitis (CTCAE greater than grade 2)
- Age 18 years or older
- Able to swallow capsules
- Willing to provide blood and stool samples
- Accessible for treatment and follow-up visits
- Agreement to use highly effective contraception if of childbearing potential
You will not qualify if you...
- Prior or concurrent malignancy that could interfere with safety or efficacy assessment
- Presence of colostomy
- Prior diagnosis of malabsorption
- Untreated chronic hepatitis B or C infection
- Solid organ transplant recipients
- HIV positive status
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2X 0A9
Actively Recruiting
Research Team
W
Wiam Belkaid, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here